CYP3A4 and acute myeloid leukemia: AZD1208 was generally well tolerated in a phase I trial in patients with AML and solid tumors in two dose-escalation studies, but it increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance, and was therefore withdrawn from clinical studies (60).